Clinical Trials Logo

Clinical Trial Summary

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. Once 31 flares are reported the study will be completed.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03000439
Study type Interventional
Source Pfizer
Contact Pfizer Call Center
Phone 1-800-718-1021
Email [email protected]
Status Recruiting
Phase Phase 3
Start date May 10, 2018
Completion date February 7, 2024